A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 598 in Subjects With Obesity
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs AMG 598 (Primary) ; Liraglutide (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Amgen
- 15 Oct 2019 Planned End Date changed from 12 Dec 2019 to 16 Dec 2019.
- 15 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 27 Mar 2019 Planned End Date changed from 16 Dec 2019 to 12 Dec 2019.